Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.79 |
| ▸ | MAOB | P27338 | 6/20 | 0.79 |
| ▸ | MAOA | P21397 | 3/20 | 0.79 |
| ▸ | NPC1 | O15118 | 2/20 | 0.79 |
| ▸ | POLB | P06746 | 2/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.79 |
| ▸ | RAB9A | P51151 | 3/20 | 0.73 |
| ▸ | LMNA | P02545 | 3/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.73 |
| ▸ | CRHBP | P24387 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.73 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.73 |
| ▸ | HTT | P42858 | 1/20 | 0.68 |
| ▸ | ALPL | P05186 | 1/20 | 0.64 |
| ▸ | ALPI | P09923 | 1/20 | 0.64 |
| ▸ | ALPG | P10696 | 1/20 | 0.64 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.61 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2053346 | 1.00 | MAPT (0.79) | MAPTMAOBMAOANPC1POLB | |
| SCHEMBL18906024 | 0.87 | MAPT (0.70) | MAPTMAOBMAOANPC1POLB | |
| SCHEMBL5597968 | 0.86 | MAPT (0.74) | MAPTMAOBMAOANPC1POLB | |
| SCHEMBL5598009 | 0.86 | MAPT (0.66) | MAPTMAOBMAOANPC1POLB | |
| SCHEMBL13721173 | 0.85 | MAPT (1.00) | MAPTMAOBMAOANPC1POLB | |
| SCHEMBL15155058 | 0.85 | MAPT (0.72) | MAPTMAOBMAOANPC1POLB | |
| SCHEMBL8807830 | 0.85 | MAPT (0.68) | MAPTMAOBMAOANPC1POLB | |
| SCHEMBL3096975 | 0.85 | MAPT (0.77) | MAPTMAOBMAOANPC1POLB | |
| SCHEMBL15155060 | 0.85 | MAPT (0.72) | MAPTMAOBMAOANPC1POLB | |
| SCHEMBL8807822 | 0.85 | MAPT (0.68) | MAPTMAOBMAOANPC1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109796426-A | A method of utilizing basic zeolite molecular sieve catalytic cortex cinnamomi acid decarboxylation coupling reaction | 常州大学 | 2019-05-24 | — | — | CN | disclosed |
| US-9192589-B2 | Chalcones as enhancer of antimicrobial agents | COLGATE-PALMOLIVE COMPANY (US) | 2015-11-24 | — | — | US | disclosed |
| EP-2512461-B1 | CHALCONES AS ENHANCER OF ANTIMICROBIAL AGENTS | COLGATE PALMOLIVE CO (US) | 2013-10-23 | — | — | EP | disclosed |
| EP-2512461-A1 | CHALCONES AS ENHANCER OF ANTIMICROBIAL AGENTS | Colgate-Palmolive Company (US) | 2012-10-24 | — | — | EP | disclosed |
| US-20120251464-A1 | CHALCONES AS ENHANCER OF ANTIMICROBIAL AGENTS | INDIAN INSTITUTE OF INTEGRATIVE MEDICINE (IN) | 2012-10-04 | — | — | US | disclosed |
| WO-2011075136-A1 | CHALCONES AS ENHANCER OF ANTIMICROBIAL AGENTS | COLGATE-PALMOLIVE COMPANY (US) | 2011-06-23 | — | — | WO | disclosed |
| US-7872029-B2 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | BOWEN J PHILLIP | 2011-01-18 | — | — | US | disclosed |
| US-20090018167-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | Robinson, Thomas Philip (US) | 2009-01-15 | — | — | US | disclosed |
| US-7432303-B2 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | Bowen, J. Phillip (US) | 2008-10-07 | — | — | US | disclosed |
| US-20050148599-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2005-07-07 | — | — | US | disclosed |
| US-6677350-B1 | ADMINISTERING CHALCONE-LIKE VINYLCARBONYL COMPOUNDS TO PREVENT OR TREAT MYCOBACTERIUM INFECTIONS/TUBERCULOSIS | ADVANCED LIFE SCIENCES, INC. | 2004-01-13 | — | — | US | disclosed |
| US-20030027830-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2003-02-06 | — | — | US | disclosed |
| US-6462075-B1 | USE OF CHALCONE AND ITS DERIVATIVES AS ANTITUMOR/ANTICANCER AGENTS AND TO TREAT A NUMBER OF CONDITIONS OR DISEASE STATES IN WHICH ANGIOGENESIS IS A FACTOR INCLUDING PSORIASIS, ACNE, ROSACEA, WARTS, ECZEMA, HEMANGIOMAS AND LYMPHANGIOGENESIS | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2002-10-08 | — | — | US | disclosed |
| EP-1242352-A2 | CHALCONE AND ITS ANALOGS AS AGENTS FOR THE INHIBITION OF ANGIOGENESIS AND RELATED DISEASE STATES | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2002-09-25 | — | — | EP | disclosed |
| EP-1217995-A2 | ANTI-MYCOBACTERIUM COMPOSITIONS AND METHODS OF PREPARING AND USING SAME | Advanced Life Sciences Inc. (US) | 2002-07-03 | — | — | EP | disclosed |
| US-20020040029-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | BOWEN, J. PHILLIP | 2002-04-04 | — | — | US | disclosed |
| WO-2001046110-A2 | CHALCONE AND ITS ANALOGS AS AGENTS FOR THE INHIBITION OF ANGIOGENESIS AND RELATED DISEASE STATES | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2001-06-28 | — | — | WO | disclosed |
| WO-2001021164-A2 | ANTI-MYCOBACTERIUM COMPOSITIONS AND METHODS OF PREPARING AND USING SAME | ADVANCED LIFE SCIENCES, INC. (US) | 2001-03-29 | — | — | WO | disclosed |
| US-4035395-A | Process for the preparation of ketones | BAYER AKTIENGESELLSCHAFT (DT) | 1977-07-12 | — | — | US | disclosed |
| US-3989708-A | HYPOTENSIVE, CORONARY VESSEL DILATORS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040029-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | FLT1, FLT4, VEGFA | MAPT 1111/4885MAOB 2579/4885MAOA 1927/4885 |
| US-20090018167-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | FLT1, FLT4, VEGFA | MAPT 1274/4885MAOB 2526/4885MAOA 1978/4885 |
| US-20030027830-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | FLT1, VEGFA, FLT4 | MAPT 341/4885MAOB 1509/4885MAOA 1059/4885 |
| US-20120251464-A1 | CHALCONES AS ENHANCER OF ANTIMICROBIAL AGENTS | LSS, CYP51A1, ELANE | MAPT 3666/4885MAOB 2787/4885MAOA 3110/4885 |
| US-20050148599-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | FLT1, VEGFA, FLT4 | MAPT 341/4885MAOB 1509/4885MAOA 1059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.